intravitreal anti-vascular endothelial growth factor use in France during COVID-19 pandemic


What The Study Did:

This study quantified changes in the use of intravitreal (IVT) anti-vascular endothelial growth factors (anti-VEGF), the main treatment for retinal vascular abnormalities, since the COVID-19 pandemic started in France.


Authors:

Sophie Billioti de Gage, Pharm.D., P.D., of EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance in Saint-Denis, France, is the corresponding author.


To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jamaophthalmol.2020.5594)


Editor’s Note:

Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###


Media advisory:

The full study is linked to this news release.


Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jamaophthalmology/

fullarticle/

10.

1001/

jamaophthalmol.

2020.

5594?guestAccessKey=

4c61f110-140e-479d-a7a6-6f2f22c034ad&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

121720

This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-12/jn-iae121520.php

withyou android app